Cargando…
Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review)
Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway d...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961124/ https://www.ncbi.nlm.nih.gov/pubmed/24660026 http://dx.doi.org/10.3892/etm.2014.1494 |
_version_ | 1782308233301458944 |
---|---|
author | ZHANG, TING ZHOU, XIANGDONG |
author_facet | ZHANG, TING ZHOU, XIANGDONG |
author_sort | ZHANG, TING |
collection | PubMed |
description | Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway diseases and critically affects the lung function, quality of life, hospitalization rate and mortality of patients with chronic inflammatory airway diseases. Therefore, expectorant therapies targeting the potential mechanisms of mucus hypersecretion have been the focus of numerous studies. Conventional expectorants are mainly mucoactive medicines, including nausea-stimulating expectorants, mucolytics, mucokinetics, and proteases and nucleases. In addition, certain traditional Chinese herbal medicines and non-mucoactive agents, including muscarinic acetylcholine receptor antagonists, corticosteroids, leukotriene receptor antagonists and macrolide antibiotics, have also shown expectorant effects. Several novel medicines for expectorant therapy have emerged, including cholesterol-lowering statins, epidermal growth factor receptor tyrosine kinase inhibitors, phosphodiesterase-4 inhibitors, stanozolol, surfactants, flavonoids, tachykinin receptor antagonists, protease inhibitors, cytokine antagonists and purinergic agonists. With the increasing number of multidisciplinary studies, the effectiveness of expectorant therapy for the treatment of chronic inflammatory airway diseases has been confirmed. Therefore, the development of novel expectorants and the standardization of expectorant therapy are the direction and focus of future studies, thus benefiting patients who have a chronic inflammatory airway disease. |
format | Online Article Text |
id | pubmed-3961124 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-39611242014-03-21 Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) ZHANG, TING ZHOU, XIANGDONG Exp Ther Med Articles Airway mucus hypersecretion is a significant clinical and pathological feature of chronic inflammatory airway diseases. Its clinical presentations include recurrent coughing and phlegm. Airway mucus is closely associated with the occurrence, development and prognosis of chronic inflammatory airway diseases and critically affects the lung function, quality of life, hospitalization rate and mortality of patients with chronic inflammatory airway diseases. Therefore, expectorant therapies targeting the potential mechanisms of mucus hypersecretion have been the focus of numerous studies. Conventional expectorants are mainly mucoactive medicines, including nausea-stimulating expectorants, mucolytics, mucokinetics, and proteases and nucleases. In addition, certain traditional Chinese herbal medicines and non-mucoactive agents, including muscarinic acetylcholine receptor antagonists, corticosteroids, leukotriene receptor antagonists and macrolide antibiotics, have also shown expectorant effects. Several novel medicines for expectorant therapy have emerged, including cholesterol-lowering statins, epidermal growth factor receptor tyrosine kinase inhibitors, phosphodiesterase-4 inhibitors, stanozolol, surfactants, flavonoids, tachykinin receptor antagonists, protease inhibitors, cytokine antagonists and purinergic agonists. With the increasing number of multidisciplinary studies, the effectiveness of expectorant therapy for the treatment of chronic inflammatory airway diseases has been confirmed. Therefore, the development of novel expectorants and the standardization of expectorant therapy are the direction and focus of future studies, thus benefiting patients who have a chronic inflammatory airway disease. D.A. Spandidos 2014-04 2014-01-21 /pmc/articles/PMC3961124/ /pubmed/24660026 http://dx.doi.org/10.3892/etm.2014.1494 Text en Copyright © 2014, Spandidos Publications http://creativecommons.org/licenses/by/3.0 This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
spellingShingle | Articles ZHANG, TING ZHOU, XIANGDONG Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) |
title | Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) |
title_full | Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) |
title_fullStr | Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) |
title_full_unstemmed | Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) |
title_short | Clinical application of expectorant therapy in chronic inflammatory airway diseases (Review) |
title_sort | clinical application of expectorant therapy in chronic inflammatory airway diseases (review) |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3961124/ https://www.ncbi.nlm.nih.gov/pubmed/24660026 http://dx.doi.org/10.3892/etm.2014.1494 |
work_keys_str_mv | AT zhangting clinicalapplicationofexpectoranttherapyinchronicinflammatoryairwaydiseasesreview AT zhouxiangdong clinicalapplicationofexpectoranttherapyinchronicinflammatoryairwaydiseasesreview |